Inside This Issue  by unknown
NOVEMBER 22, 2011
VOLUME 58, NO. 22
JOURNAL of the AMERICAN COLLEGE of CARDIOLOGY
Inside This Issue
STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER
2263Safety and Efficacy of Antiplatelet and
Antithrombotic Therapy in ACS Patients With CKDSukhdeep S. Basra, Peter Tsai, Nasser M. Lakkis
Chronic kidney disease (CKD) is common in patients with acute coronary syndromes (ACS).
ACS patients with CKD have significantly higher mortality, due to both thrombotic and
bleeding complications. Most randomized trials of antiplatelet and antithrombotic drugs
excluded patients with CKD, limiting the utility of these trials for guiding therapeutic
decisions. Basra and colleagues review the data regarding the safety and efficacy of these drugs
in this unique patient population, with a special emphasis on how the dose of these drugs
should be adjusted for varying degrees of renal insufficiency.CLINICAL RESEARCH HEART FAILURE
2270Expression of Certain Microribonucleic Acids May Predict
Which Patients Will Recover LV Function With VAD TherapyRavi Ramani, Deborah Vela, Ana Segura, Dennis McNamara, Bonnie Lemster, Vishnupriya Samarendra,
Robert Kormos, Yoshiya Toyoda, Christian Bermudez, O. H. Frazier, Christine S. Moravec, John Gorcsan III,
Heinrich Taegtmeyer, Charles F. McTiernan
Microribonucleic acids (miRs) are short, noncoding ribonucleic acids that play an important
role in post-transcriptional regulation of gene expression. Ramani and colleagues tested the
hypothesis that profiling cardiac miRs from left ventricular (LV) biopsy samples at the time
of ventricular assist device (VAD) placement would differentiate those patients who remained
VAD-dependent from those with subsequent LV recovery. By polymerase chain reaction
array, 10 miRs were differentially expressed between LV recovery and VAD-dependent
patients. Further confirmatory testing showed that 2 of the miRs were especially useful, with
low levels identifying those VAD recipients likely to recover LV function.
Editorial Comment: Douglas L. Mann, Daniel Burkhoff, p. 2279(continued on page A-25)
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2282Reduced Frequency of Ventricular Arrhythmias in
Patients With a Positive Response to CRTJoep Thijssen, C. Jan Willem Borleffs, Victoria Delgado, Johannes B. van Rees, Eline A. Q. Mooyaart,
Rutger J. van Bommel, Lieselot van Erven, Eric Boersma, Jeroen J. Bax, Martin J. Schalij
Cardiac resynchronization therapy (CRT) may either decrease the frequency of ventricular
arrhythmias (VAs) by reducing ventricular conduction delays or increase the risk by reversing
the direction of activation of the left ventricular wall. Thijssen and colleagues compared the
rate of subsequent VAs in patients who were “upgraded” from an implantable cardioverter-
defibrillator to a CRT defibrillator stratified by whether or not the ventricle showed reverse
remodeling in response to the CRT therapy. Compared with their history prior to CRT
upgrade, in CRT responders, the frequency of VAs requiring appropriate device therapy
decreased 0.51 to 0.30 per patient per year, while the rate increased in CRT nonresponders.HEART RHYTHM DISORDERS
2290Novel ECG Criteria for Discriminating Brugada
Type 2 and 3 Patterns From Incomplete RBBBStéphane Chevallier, Andrei Forclaz, Joanna Tenkorang, Yannis Ahmad, Mohamed Faouzi, Denis Graf,
Juerg Schlaepfer, Etienne Pruvot
Brugada syndrome (BrS) can manifest as type 2 or 3 patterns, which are similar to an
incomplete right bundle branch block (RBBB) pattern. Chevallier and colleagues tested
2 electrocardiographic (ECG) criteria to identify which patients had BrS, which was
diagnosed as those who developed a type 1 ECG with antiarrhythmic drug challenge. Both
measurements used the angle from the downslope of the r=-wave: 1) , the angle between a
ertical line and the downslope of the r=-wave; and 2) , the angle between the upslope of
he S-wave and the downslope of the r=-wave.  was found to be significantly higher in those
with BrS. As an accompanying editorial explains, the r= in incomplete RBBB is taller and
narrower than the r=-wave in patients with BrS.
Editorial Comment: Pedro Brugada, p. 2299(continued on page A-26)
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2301NGAL and Other Biomarkers Predict Acute Kidney Injury
After Pediatric Cardiopulmonary BypassCatherine D. Krawczeski, Stuart L. Goldstein, Jessica G. Woo, Yu Wang, Nuntawan Piyaphanee, Qing Ma,
Michael Bennett, Prasad Devarajan
Krawczeski and colleagues investigated the temporal pattern and predictive value (alone and
in combination) of 4 urinary biomarkers for diagnosing acute kidney injury (AKI) in pediatric
patients after cardiac surgery. AKI was defined as a 50% increase in serum creatinine from
baseline. Urine neutrophil gelatinase-associated lipocalin (NGAL) significantly increased in
AKI patients at 2 h after cardiopulmonary bypass initiation. Interleukin-18 and liver fatty
acid-binding protein increased at 6 h, and kidney injury molecule-1 increased at 12 h.
Biomarker elevations correlated with AKI severity and clinical outcomes. These biomarkers,
particularly in combination, may help establish the timing of injury and allow for earlier
intervention in AKI.Editorial Comment: Michael Haase, Anja Haase-Fielitz, p. 2310CARDIOMYOPATHY
2313No Difference in Long-Term Survival for Invasive Therapy
to Relieve the Resting Gradient in Patients With Obstructive HCMWarren Ball, Joan Ivanov, Harry Rakowski, E. Douglas Wigle, Meredith Linghorne,
Anthony Ralph-Edwards, William G. Williams, Leonard Schwartz, Ashley Guttman, Anna Woo
In patients with resting obstructive hypertrophic cardiomyopathy (HCM), symptoms can be
improved with invasive septal reduction therapy; however, it remains controversial how this
affects long-term survival. Ball and colleagues studied a consecutive cohort of 649 patients
with resting obstructive HCM. A total of 35% were conservatively managed, and the rest
were invasively managed by surgical myectomy, septal ethanol ablation, or dual-chamber
pacing. There was a significant reduction in total mortality with invasive management;
however, there was no difference in HCM-related mortality. Because patients were not
randomized, these results suggest that healthier patients are more likely to undergo invasive
therapy, while also suggesting that invasive therapy is unlikely to improve mortality.(continued on page A-32)
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2322Registry Results Define Short- and Long-Term Outcomes
After Alcohol Septal Ablation for HOCMSherif F. Nagueh, Bertron M. Groves, Leonard Schwartz, Karen M. Smith, Andrew Wang,
Richard G. Bach, Christopher Nielsen, Ferdinand Leya, John M. Buergler, Steven K. Rowe, Anna Woo,
Yolanda Munoz Maldonado, William H. Spencer III
Nagueh and colleagues reviewed results from a multicenter registry of over 800 patients with
medically refractory hypertrophic obstructive cardiomyopathy (HOCM) who underwent
alcohol septal ablation using standardized protocols for evaluation and management. Before
ablation, 75% of patients were in New York Heart Association functional class III or IV;
after ablation, only 5% were in class III or IV. Survival estimates at 1, 5, and 9 years were
97%, 86%, and 74%, respectively. Variables that were found to predict mortality after ablation
included lower baseline ejection fraction, higher number of septal arteries injected with
ethanol, greater post-ablation septal thickness, beta-blocker use, and the number of ablation
procedures that the patient underwent.Editorial Comment: Perry Elliott, p. 2329PRE-CLINICAL RESEARCH PRE-CLINICAL RESEARCH
2332Inhibition of c-Src Tyrosine Kinase Prevents Angiotensin II-Mediated
Cx43 Remodeling and Sudden Cardiac Death in Mouse ModelAli A. Sovari, Shahriar Iravanian, Elena Dolmatova, Zhe Jiao, Hong Liu, Shadi Zandieh, Vibhash Kumar,
Kun Wang, Kenneth E. Bernstein, Marcelo G. Bonini, Heather Duffy, Samuel C. Dudley
Renin-angiotensin system (RAS) activation increases the risk of arrhythmia and sudden
cardiac death, but the mechanism is not well understood. Some research suggests that it is
related to up-regulation of c-Src and a reduction of connexin-43 (Cx43), which regulates gap
junction function. Sovari and colleagues studied this in a transgenic mouse model of cardiac-
restricted overexpression of angiotensin-converting enzyme by treating some mice with the
c-Src inhibitor PP1. PP1 reduced c-Src levels, increased the Cx43 levels, improved gap
junction communication, and reduced ventricular tachycardia inducibility and sudden cardiac
death. These results suggest that an increase in c-Src may underlie RAS-induced arrhythmias
and that c-Src inhibitors may have antiarrhythmic activity.Editorial Comment: Peng-Sheng Chen, Tomohiko Ai, p. 2340YEAR IN CARDIOLOGY SERIES YEAR IN CARDIOLOGY SERIES2342The Year in Non–ST-Segment Elevation Acute Coronary SyndromeRobert P. Giugliano, Eugene Braunwald
Giugliano and Braunwald review the last year’s research and other publications related to the
diagnosis, treatment, and prognosis for patients with non–ST-segment elevation acute
coronary syndrome.
